Inscripta is thrilled to welcome Infinome Biosciences and Sestina Bio to the team. We have never been more excited about the future of the bioeconomy and how we can create a better way of making products the world needs. bit.ly/3Hbyc7I #biomanufacturing #bioeconomy

Groundbreaking News! Andrew Horwitz, VP of Research and Development, Sestina Bio, LLC. explains how Inscripta’s #Onyx platform helped accelerate their goals to produce a #sustainable #biomanufacturing process for Bakuchiol! inscripta.com/news/sestina-b…

This Sunday is #juneteenth2022. At #Inscripta, we commit ourselves to building a workplace that celebrates inclusion and empowerment. So, we take this time to recognize the contributions of Black Americans in history that have paved the way for equity, equality, and justice.

On June 23rd #Inscripta’s CEO Sri Kosaraju will join other #synbio industry leaders at the 2022 @Barclays Bio-Builders Summit where they will discuss how biology-based manufacturing supports #sustainability & innovation. There is still time to register: events.barclays.com/website/…

Inscripta celebrates #pride2022. This month and always, let’s shine a light on diversity, equity, and inclusion by uplifting and supporting #LGBTQIA voices, culture, and rights.

You may not be able to #engineer your E.coli cells into a puppy but you can use the #Onyx platform to create thousands of different strains in the span of just weeks and see what you can #discover. #genomeengineering #geneediting #syntheticbiology #biotech

Have you ever tried to produce a protein in a ready-to-use strain & ended up spending months optimizing its expression? Luckily, we've developed a simple way to customize your strain to achieve the best #protein yields. Register for webinar to learn how: bit.ly/3MPKQZQ

In case you missed our May #webinar, you can now watch the recording on our website: bit.ly/3Nqhx0y Learn how to match your #strainengineering and #phenotyping capacity using the #shallowscreening approach.

The co-location of the gRNA, edit & barcode on a single construct makes it possible to perform genome-wide editing with thousands of edits in a single experiment and unprecedented efficiency. Learn more about our #Onyx benchtop #genomeengineering platform: inscripta.com/technology/dig…

@InscriptaInc & @aldevron have signed a licensing agreement for the manufacturing of Inscripta's MAD7™ nuclease. A partnership between two CRISPR pioneers will provide the global scientific community with RUO & GMP-grade MAD7 nuclease. Read the details: bit.ly/3lbBPPg